Biogen Idec Inc. company logo

# 1st Gen Model Biogen Idec Inc. Biological products, except diagnostic

  • $280.57Last close price
    at 22-jun-2017
  • Subscribe >> Deal exit on
    June 23, 2017
    Deal entry on
    June 23, 2017
  • 5.70%Expected margin
  • 53.33% successful of 60 deals

BIIB

Model's trade recommendations -0.43% Return for period

-4.83% Annual return

$59.51B Market Cap

β 0.83  

BIIB

Model (following trade recommendations)

BIIB

Underlying stock

S&P 500

Index
Return for period -0.43%
10.91%
1.78%
52wk return -23.45%
17.58%
16.82%
52wk Range
224.60—330.11
2000.54—2399.63
Sortino ratio -0.38
Sharpe ratio -0.28
Norm. RMSE 0.39%
Downside risk 11.10%
Volatility 14.79%
  • STRONG BUY Analysts consensus recommendation

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.

Industry sector: Medical

Sector classification: Biological products, except diagnostic

Deep Learning based analysis and prediction model for Biogen Idec Inc. (BIIB) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for BIIB model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 213M
P/E 13.50
Shares Outstanding 214M
% Held by Insiders 0.32%
% Held by Institutions 87.39%
EPS (last reported FY) $20.22
EPS (last reported Q) $5.20
EPS, estimated (last reported Q) $4.97
Total revenues $11 B
Net income $4 B